SCHAFFHAUSEN, Suiza, 20 de octubre de 2014 /PRNewswire/ --Pharmacyclics Switzerland GmbH, una filial de Pharmacyclics, Inc. (NASDAQ: PCYC ), ha anunciado hoy que la Comisión Europea (CE) ha concedido una autorización de marketing para IMBRUVICA ... PR Newswire, 1 month ago
3 images for "Ibrutinib"
Janssen Inc. has announced Health Canada has approved IMBRUVICA (ibrutinib) for the treatment of the blood cancer chronic lymphocytic leukemia (CLL). It is indicated for the treatment of patients with CLL, including those with 17p deletion, who have ...Medical News Today, 2 days ago Pharmacyclics Inc announces IMBRUVICA (ibrutinib) approved in Europe for treatment of two blood cancers Reuters, 1 month ago Health Canada Approves IMBRUVICA by Priority Review, Giving Physicians and Patients a Much-Needed Option in the Fight Against Chronic Lymphocytic Leukemia Canada NewsWire, 3 days ago Health Canada Approves IMBRUVICA(TM) by Priority Review, Giving Physicians and Patients a Much-Needed Option in the Fight Against Chronic Lymphocytic Leukemia Canada NewsWire, 3 days ago
IMBRUVICA® (ibrutinib) Data to be Presented Across Multiple Histologies, Including in Eight Oral Presentations, at 2014 American Society of Hematology (ASH) Annual Meeting
News Story Sorry, the story you were looking for is not available. Back to News Tweet Radar -ALLSYMB- AIG GOOG Scroll over any stock symbol to predict whether that stock's value will go up or down and to view other valuable ...PredictWallStreet, 2 weeks ago IMBRUVICA ibrutinib Supplemental New Drug Application Submitted to the U.S. FDA for Waldenstrom's macroglobulinemia Pharmacy Choice, 2 weeks ago AstraZeneca And Pharmacyclics Enter Immuno-Oncology Clinical Trial Collaboration With IMBRUVICA® In Solid Tumors ADVFN UK, 2 weeks ago TG Therapeutics, Inc. Announces Data Presentations at the Upcoming 56th American Society of Hematology Annual Meeting Morningstar.com, 2 weeks ago
New Chronic Lymphocytic Leukemia Findings Has Been Reported by Investigators at Pharmacyclics Inc. (Ibrutinib inhibits BCR and NF-kappa B signaling...
New Chronic Lymphocytic Leukemia Findings Has Been Reported by Investigators at Pharmacyclics Inc. (Ibrutinib inhibits BCR and NF-kappa B signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL) By a News ...4 Traders, 3 weeks ago Data from Pharmacyclics Inc. Advance Knowledge in Chronic Lymphocytic Leukemia (Kinetics of CLL cells in tissues and blood during therapy with the... 4 Traders, 3 weeks ago
Janssen-Cilag International NV (Janssen) has announced that the European Commission has approved ibrutinib (imbruvica)capsules, a first-in-class, once-daily, oral Bruton's tyrosine kinase (BTK) inhibitor. This new approach to treating blood ...Ecancer Medicalscience, 1 month ago EMA Approves Blood Cancer Drug Imbruvica for Two Indications FDA News, 4 weeks ago
Johnson & Johnson (NYSE:JNJ) has entered a partnership with Geron to develop its blood cancer treatment candidate, Imetelstat. The news sent the shares of Geron up by 40%, which means that for Geron's investors this is a big deal. As far as J&J is ...Trefis, 3 days ago Johnson & Johnson: Still A Solid Dividend Growth Pick Seeking Alpha, 2 weeks ago
The market for Non Hodgkin Lymphoma has significant unmet medical necessities in terms of demand for innovative drugs and novel technologies. This is one of the major factors behind the market witnessing rapid growth in Non Hodgkin Lymphoma segment.Global Information Inc, 2 days ago Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020 - New Entrants and Promising Pipeline Widen Targeted and Immunotherapeutic Treatment Options Minyanville, 1 week ago The Report Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets to 2020 - Novel Technologies Show Considerable Promise in Relapsed/Refractory Setting Digital Journal, 1 week ago Non-Hodgkin lymphoma market to grow to $9.2 billion Pharma Letter, 3 weeks ago
According to IMS Health (NYSE:IMS) global drug spending will top $1T this year led by Gilead's (NASDAQ:GILD) Sovaldi (sofosbuvir) for hep C and new cancer drugs. The projected spend of $1.06T represents a 7% increase from last year. By 2018, drug ...Seeking Alpha, 2 days ago
Kadcyla (ado-trastuzumab emtansine) is among the drugs driving high prices Worldwide spending on drugs will reach over $1 trillion in 2014 and $1.3 trillion by 2018, according to a new report. The study by the IMS Institute for Healthcare ...Pharmafocus, 2 days ago
When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies haven't yet entirely recouped the losses. The ...BioMedReports, 3 days ago What's Done Better for Investors: Small Biotechs or Big Pharma? Equities.com, 1 week ago
More from: , VideoBasedTutorials...and 5 other sources
on your WebpageAdd Widget >Get your members hooked!